Achmea Investment Management B.V. Sells 122,509 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Achmea Investment Management B.V. lowered its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 14.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 738,385 shares of the company's stock after selling 122,509 shares during the quarter. Achmea Investment Management B.V. owned 0.07% of Teva Pharmaceutical Industries worth $11,349,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Oarsman Capital Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $29,000. Golden State Wealth Management LLC bought a new stake in Teva Pharmaceutical Industries during the 1st quarter worth about $39,000. Marshall & Sterling Wealth Advisors Inc. bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at about $44,000. Compagnie Lombard Odier SCmA acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at about $54,000. Finally, Versant Capital Management Inc raised its holdings in Teva Pharmaceutical Industries by 437.8% during the first quarter. Versant Capital Management Inc now owns 5,297 shares of the company's stock worth $81,000 after acquiring an additional 4,312 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president directly owned 9,989 shares of the company's stock, valued at $170,012.78. This trade represents a 38.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA traded down $0.11 during trading hours on Tuesday, reaching $16.65. 10,695,450 shares of the stock were exchanged, compared to its average volume of 10,281,492. The firm has a market capitalization of $19.10 billion, a price-to-earnings ratio of -14.48, a P/E/G ratio of 0.86 and a beta of 0.60. The stock's fifty day simple moving average is $16.79 and its 200 day simple moving average is $17.40. The company has a debt-to-equity ratio of 2.59, a quick ratio of 0.74 and a current ratio of 1.03. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The company had revenue of $3.89 billion during the quarter, compared to analysts' expectations of $3.99 billion. During the same quarter in the previous year, the business posted $0.48 earnings per share. Teva Pharmaceutical Industries's quarterly revenue was up 1.9% on a year-over-year basis. Sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Wall Street Analyst Weigh In

TEVA has been the subject of several analyst reports. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $21.00 to $23.00 in a research report on Monday, May 12th. UBS Group dropped their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Finally, Bank of America boosted their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Teva Pharmaceutical Industries has an average rating of "Buy" and an average target price of $24.13.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.